Everest Medicines (SEHK:1952) Eyes Growth with EVER001 Launch and AI Investments Despite Profitability Concerns

Everest Medicines (SEHK:1952) anticipates a 37.2% annual revenue growth driven by EVER001 introduction. Challenges include unprofitability and cost management issues.